Newer antibiotic effective against deadly staph infection in trial

Sept 27 (Reuters) – An antibiotic already in use in Europe to treat pneumonia controlled deadly bloodstream infections with Staphylococcus aureus bacteria just as effectively as the most powerful antibiotic currently in use, according to data from a late-stage trial.

Ceftobiprole from Swiss drugmaker Basilea Pharmaceutica (BSLN.S) appeared to be equally effective as the older drug daptomycin in the roughly one-in-four patients who had particularly difficult to treat methicillin-resistant S. aureus (MRSA) infections, researchers reported on Wednesday in The New England Journal of Medicine.

“This is an area of true need,” study leader Dr. Thomas Holland of Duke University School of Medicine said in a statement. “There has not been a new antibiotic approved for the treatment of S. aureus bacteremia for over 15 years.”

For the study, 390 patients hospitalized with complicated bloodstream staph infections were randomly assigned to receive infusions of ceftobiprole or daptomycin.

The treatment was successful in 69.8% of the ceftobiprole group and 68.7% of the daptomycin group, according to the report. Success was defined as survival, symptom improvement, clearance of S. aureus from the blood, absence of new complications and no need for other antibiotics.

Gastrointestinal issues were the most common side effect with both drugs.

Daptomycin was the most recently approved new antibiotic for S. aureus bacteremia more than 15 years ago, the researchers noted.

“Despite a lot of work in medical science, complicated staph infections still have a 25% mortality rate at 90 days,” study co-author Dr. Vance Fowler Jr. of Duke Health said in a statement. “We need more options for treating these infections.”

In August, Basilea Pharmaceutica filed for approval of ceftobiprole with the U.S. Food and Drug Administration.

Keep up with the latest medical breakthroughs and healthcare trends with our newsletter Reuters Health Rounds. Sign up here.

Reporting by Nancy Lapid; editing by Bill Berkrot

私たちの行動規範:トムソン・ロイター「信頼の原則」

Acquire Licensing Rights, opens new tab

Nancy Lapid

トムソン・ロイター

Nancy has been a health news editor at Reuters for more than a decade. Previously she was a writer and editor for medical centers around the world, helping researchers report on their studies for scientific journals and major meetings. Here at Reuters, Nancy is dedicated to bringing our readers what they need to know about important research advances in timely and engaging stories and in our twice-a-week Reuters Health rounds newsletter.
Contact: 347-266-6958

Leave a Reply

Your email address will not be published. Required fields are marked *